The National Cancer Institute (NCI) awarded a $569,441 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Wisconsin - Madison to conduct research on the regulation of nuclear AKT by p53, MDM2, and phosphoinositide lipids, and their roles in oncogenic transformation and tumor progression. The 5-year project aims to investigate the mechanisms by which a nuclear PI3K/AKT pathway scaffolded on p53 is activated, how this pathway is differentially regulated between wild-type and mutant p53, and the functional implications for tumor suppression and progression. As part of the project, the University of Connecticut Health Center was awarded a sub-grant to systematically investigate the interaction of regulatory signaling enzymes with p53. This multifaceted research effort seeks to elucidate fundamental cancer biology mechanisms with the potential to lead to new diagnostic, preventive, or therapeutic approaches.
Generated 3/18/25, 4:55 AM